ABVX sentiment intelligence

Principal Financial Group Inc. Increases Holdings in Abivax SA Sponsored ADR $ABVX

Principal Financial Group Inc. significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 43.3% in the first quarter, bringing its total holdings to 312,274 shares valued at approximately $34.8 million. Other institutional investors have also adjusted their pos

Tone

Positive 71/100

Event

Earnings

Published

19 Jul 2026 08:40

Source

MarketBeat

Brummer Multi Strategy AB Boosts Position in Abivax SA Sponsored ADR $ABVX

Brummer Multi Strategy AB significantly increased its stake in Abivax SA, boosting its holdings by 56% to 22,428 shares, now representing 10.4% of its portfolio. This move aligns with a "Moderate Buy" consensus from analysts, who have set price targets as high as $187. Abivax rec

Tone

Positive 74/100

Event

Deals and strategy

Published

17 Jul 2026 08:41

Source

MarketBeat

Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates

Valerio Therapeutics and Abivax have announced a research and development agreement to identify new drug candidates for inflammatory diseases. The collaboration aims to leverage the expertise of both companies to advance treatment options in this therapeutic area.

Tone

Positive 71/100

Event

Deals and strategy

Published

17 Jul 2026 02:10

Source

Moomoo

Diversify Wealth Management LLC Purchases 14,626 Shares of Abivax SA Sponsored ADR $ABVX

Diversify Wealth Management LLC significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the first quarter by 470.3%, acquiring an additional 14,626 shares. This brings their total holding to 17,736 shares, valued at approximately $1.88 million. Abivax re

Tone

Positive 66/100

Event

Earnings

Published

15 Jul 2026 08:14

Source

MarketBeat

ABIVAX (ABVX) Corporate presentation Summary

The corporate presentation summary for ABIVAX (ABVX) highlights its drug obefazimod, currently in Phase 3 trials for ulcerative colitis (UC) and Phase 2b for Crohn's disease (CD), with key data expected through mid-2027. Obefazimod, an oral small molecule enhancing miR-124, targe

Tone

Positive 72/100

Event

Market update

Published

15 Jul 2026 01:41

Source

Quartr

Candriam S.C.A. Takes $4.01 Million Position in Abivax SA Sponsored ADR $ABVX

Candriam S.C.A. has initiated a significant position in Abivax SA Sponsored ADR (NASDAQ:ABVX), acquiring 36,061 shares valued at approximately $4.01 million in the first quarter. This move comes as other institutional investors like Millennium Management and Woodline Partners hav

Tone

Positive 72/100

Event

Earnings

Published

14 Jul 2026 08:12

Source

MarketBeat

Precision Trading with Abivax Sa (ABVX) Risk Zones

This article provides a precision trading analysis for Abivax Sa (ABVX), highlighting a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—wit

Tone

Positive 71/100

Event

Guidance

Published

12 Jul 2026 08:46

Source

Stock Traders Daily

ABIVAX Société Anonyme (ENXTPA:ABVX) Could Be 44% Undervalued As UC Data Lands

ABIVAX Société Anonyme (ENXTPA:ABVX) is considered 44% undervalued by analysts, trading below its implied fair value of €220 despite a recent share price run and new positive data for its ulcerative colitis candidate, obefazimod. The company has also secured sufficient funding fo

Tone

Positive 73/100

Event

Market update

Published

11 Jul 2026 00:11

Source

Simply Wall Street

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

Tone

Positive 58/100

Event

Market update

Published

10 Jul 2026 13:55

Source

Zacks

Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma

Abivax CEO Marc de Garidel announced that a recent $920 million share offering provides the company with sufficient funds to independently launch its bowel disease drug, obefazimod, in the U.S. through 2029. This funding allows them to avoid partnering with a larger pharmaceutica

Tone

Positive 71/100

Event

Market update

Published

10 Jul 2026 14:39

Source

Quartz

Piper Sandler raises Abivax stock price target to $175 on UC data

Piper Sandler has increased its price target for Abivax (NASDAQ: ABVX) to $175 from $165, maintaining an Overweight rating, following positive ulcerative colitis data and recent equity financing. The firm boosted its 2035 U.S. ulcerative colitis revenue estimates for obefazimod t

Tone

Positive 71/100

Event

Analyst action

Published

10 Jul 2026 11:40

Source

Investing.com

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

Abivax secured $920 million in funding, allowing the French biotech to independently launch its bowel disease drug, obefazimod, in the U.S. without needing a Big Pharma acquisition. CEO Marc de Garidel stated this funding provides cash until late 2029 and positions the company fo

Tone

Positive 71/100

Event

Deals and strategy

Published

10 Jul 2026 10:12

Source

CNBC

Best defense is the offence, says Abivax CEO after takeover speculation

Abivax CEO Marc de Garidel discussed the company's clinical trials and recent takeover speculation. He stated that "Best defense is the offense" in response to questions about the company's strategy amid these speculations.

Tone

Positive 64/100

Event

Market update

Published

10 Jul 2026 10:12

Source

CNBC

Abivax: Wall Street Catches Up to the Data

Shares of Abivax (NASDAQ: ABVX) surged over 40% after positive Phase 3 trial results for its ulcerative colitis drug, Obefazimod, and a successful $920 million share offering. Despite an initial dip due to a cancer-related safety signal, subsequent data reinforced the drug's safe

Tone

Positive 71/100

Event

Earnings

Published

08 Jul 2026 11:40

Source

The Globe and Mail

Wedbush Raises Price Target on Abivax to $140 From $110, Keeps Neutral Rating

Tone

Positive 58/100

Event

Analyst action

Published

06 Jul 2026 10:52

Source

MT Newswires

StockWatch: New UC Data Sparks Smoother Sailing for Abivax

Shares of French biotech company Abivax surged after the company released positive new data from its Phase III maintenance program for obefazimod, its lead candidate for ulcerative colitis. The data showed meaningful clinical benefit and, crucially, no new safety signals, easing

Tone

Positive 73/100

Event

Market update

Published

05 Jul 2026 21:16

Source

Genetic Engineering and Biotechnology News

Is ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?

Tone

Positive 66/100

Event

Market update

Published

03 Jul 2026 07:00

Source

Market source

ABVX Stock Eyes Over Six-Month High As US Commercialization Plans Gain Momentum – Retail Eyes Potential Buyout

Abivax (ABVX) shares are nearing a six-month high after underwriters fully exercised an option to purchase an additional 960,000 American depositary shares, raising total proceeds to $874.1 million. The funds will support the potential U.S. commercialization of its lead drug Obef

Tone

Positive 71/100

Event

Market update

Published

02 Jul 2026 10:09

Source

Stocktwits

Abivax Prices $800M Offering Of ADS – Here’s A Look At Some Key Figures

Abivax announced the pricing of an upsized underwritten public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, increasing the offering size from $600 million to $800 million. The company expects these proceeds, combined with existing cash, to extend its op

Tone

Positive 75/100

Event

Guidance

Published

02 Jul 2026 09:09

Source

Stocktwits